Some cancer medicines slow the heart's electrical reset between beats, seen on a heart tracing (ECG) as a long QT interval. Rarely this sets off a dangerous rhythm. Your team should do an ECG and check your blood salts before you start, review your other medicines, and repeat the ECG on a schedule. Get medical help straight away if you faint, feel dizzy or your heartbeat is fast or irregular.
Before a QT-prolonging cancer medicine, record a 12-lead ECG with the QT interval corrected by the Fridericia formula (ESMO 2020 [I, A] for a baseline ECG; ESC 2022 recommends Fridericia), correct potassium, magnesium and calcium, and review every other medicine for QT-prolonging drugs and, for ribociclib, quizartinib and revumenib, strong CYP3A inhibitors. The ESC algorithm asks for potassium above 4.0 mmol/L and magnesium above 1.10 mmol/L, and for cardio-oncology evaluation before starting if QTcF is above 480 ms. The labels are stricter: ribociclib is started only below 450 ms, and quizartinib and revumenib are not started above 450 ms.
Repeat ECGs follow the product's label: ribociclib at about day 14 of the first cycle; quizartinib weekly during induction and consolidation and for at least the first month of maintenance; revumenib at least weekly for 4 weeks and then at least monthly; osimertinib and adagrasib in people at risk. ESC recommends QTc monitoring at baseline and at 14 and 28 days for everyone on ribociclib (Class I, Level A), and an ECG after any dose increase of a QT-prolonging medicine (Class I, Level C).
The action thresholds are QTcF above 480 ms and 500 ms. ESC: weekly ECGs for people without symptoms at 480 to 500 ms (Class I, Level C); at 500 ms or more, interrupt the medicine and repeat the ECG every 24 hours until it resolves (Class I, Level C), withdraw any other offending drug and correct electrolytes and other risk factors (Class I, Level C). ESC and IC-OS both say that a rise of more than 60 ms from baseline should not routinely change treatment while QTc stays below 500 ms. Labels are stricter in places: ribociclib and revumenib are interrupted above 480 ms, and adagrasib and revumenib are withheld for a rise of more than 60 ms. ESC recommends stopping the medicine after torsades de pointes or a sustained ventricular tachyarrhythmia (Class I, Level C), and every label read stops it permanently for torsades de pointes or signs of serious or life-threatening arrhythmia. Restarting after significant prolongation needs a multidisciplinary discussion first (Class I, Level C); ESC says it may be considered, ideally at a reduced dose (Class IIb, Level C), with weekly ECGs for the first 4 to 6 weeks and then monthly (Class I, Level C). Quizartinib carries a boxed warning and in the United States is supplied only through a restricted programme. This page explains care; the treating team's own protocol and the product's current label come first.
Why: Later tracings are compared with this one, and several labels set a QT limit for starting the medicine.
“For patients with a cancer diagnosis that requires treatment with a potentially cardiotoxic treatment, a baseline ECG, including measurement of heart rate QTc, is recommended”
Why: ESC says the Fridericia formula has shown less error than others such as Bazett at both high and low heart rates. ESMO says every comparison during treatment should use the same formula.
“In patients with cancer, the Fridericia formula is recommended and has demonstrated less error than other correction methods such as Bazzett at both high and low heart rates”
Why: ESC lists low potassium, magnesium and calcium as correctable risk factors for a long QT interval and torsades de pointes. The quizartinib label asks for more frequent checks in people with diarrhoea or vomiting.
“In patients treated with QTc-prolonging drugs, serum electrolytes and other risk factors should be closely monitored and corrected, and concomitant QT-prolonging drugs avoided if possible”
Why: ESC lists these drug classes among the risk factors, and the quizartinib label says that giving another QT-prolonging medicine with it may make QT prolongation more frequent.
“When feasible, avoid concomitant administration of drugs known to prolong the QTc interval with known risk of Torsades de pointes.”
AstraZeneca, on DailyMed (US National Library of Medicine) 2026
Why: The labels set these limits. The trials of quizartinib and revumenib did not include people whose QTcF was already 450 ms or more.
“Initiate treatment with KISQALI only in patients with QTcF values less than 450 ms.”
Novartis, on DailyMed (US National Library of Medicine) 2026
Why: ESC advises a cardiology consultation for these groups, and its algorithm sends anyone with a baseline QTcF above 480 ms for cardio-oncology evaluation before treatment starts.
“Cardiology consultation is advised in patients with an abnormal baseline QTc interval, patients treated with drugs that prolong the QT interval, those who develop new cardiac symptoms (syncope or pre-syncope, rapid palpitations or QTc prolongation with new-onset bradycardia, high degree of heart block), and/or those with known inherited arrhythmia disorders”
Why: The ribociclib label reports that most QT prolongation in its trials occurred within the first four weeks, and the quizartinib label that the severe rhythm problems occurred mostly during induction.
“During induction and consolidation, perform ECGs prior to initiation and then once weekly during VANFLYTA treatment or more frequently as clinically indicated”
Daiichi Sankyo, on DailyMed (US National Library of Medicine) 2026
Why: ESC names similar occasions for people at risk of QT prolongation on VEGF inhibitors, and recommends an ECG after any dose increase of a QT-prolonging cancer medicine (Class I, Level C).
“Specifically, an ECG should be obtained at baseline, once steady-state levels are achieved, with dose adjustments and with the initiation of new medications that may prolong the QT interval, or with the development of an electrolyte imbalance”
Why: The labels name these as symptoms that may go with a significantly long QT interval, and a medicine started elsewhere may also lengthen it.
“Inform patients of symptoms that may be associated with significant QTc interval prolongation including dizziness, lightheadedness, and fainting.”
Daiichi Sankyo, on DailyMed (US National Library of Medicine) 2026
Why: ESC says torsades de pointes rarely occurs below 500 ms, and its algorithm continues treatment with closer checks. The ribociclib and revumenib labels interrupt above 480 ms and the quizartinib label reduces the dose.
“Weekly ECG monitoring is recommended in asymptomatic patients with cancer with QTcF 480–500 ms who are treated with a QTc-prolonging cancer therapy”
Why: ESC says a QTc of 500 ms or more carries a two to three times higher risk of torsades de pointes. IC-OS likewise recommends considering a change of cancer treatment only above 500 ms.
“Temporary interruption of QTc-prolonging cancer therapy is recommended in patients who develop asymptomatic QTcF ≥ 500 ms and an ECG should be repeated every 24 h until resolution of the QTcF prolongation.”
Why: ESC and IC-OS say a rise of this size should not routinely affect treatment decisions below 500 ms. The adagrasib and revumenib labels do withhold the medicine for a rise of more than 60 ms.
“Changes in the QT interval of >60 ms from baseline should not routinely affect treatment decisions if the QTc remains <500 ms”
Why: The labels describe the effect on the QT interval as rising with the drug's concentration. ESC recommends a multidisciplinary discussion before restarting, and weekly ECGs for the first 4 to 6 weeks and then monthly (both Class I, Level C).
“Interrupt KISQALI treatment and wait until QTcF resolves to ≤ 480 ms, then resume at next lower dose level.”
Novartis, on DailyMed (US National Library of Medicine) 2026
Why: ESC recommends stopping after torsades de pointes or a sustained ventricular tachyarrhythmia (Class I, Level C), and all five labels read say to stop permanently.
“Permanently discontinue TAGRISSO in patients who develop QTc interval prolongation with signs/symptoms of life-threatening arrhythmia”
AstraZeneca, on DailyMed (US National Library of Medicine) 2026
Why: ESC says symptomatic ventricular arrhythmias need a dose reduction or discontinuation and referral to a cardiologist, and that recurrent, symptomatic, life-threatening ones need urgent intervention. It sets out no separate emergency procedure for people with cancer.
“Treatment of cancer therapy-induced VA should follow general clinical guidelines.”
How care is usually carried out, read from the guidelines and standards cited. Your own team's protocol and their judgement come first; this page is for understanding it, not for doing it yourself.
The 2022 ESC cardio-oncology guideline is the most recent graded guideline read. Its recommendations on managing a long QT interval (Recommendation Table 32) are all Level C, that is, expert consensus or small studies; its recommendation for QTc monitoring at baseline and at 14 and 28 days on ribociclib is Class I, Level A. ESC and ESMO (2020) recommend a baseline ECG. ESC and IC-OS (2022) recommend the Fridericia correction; ESMO accepts Bazett or Fridericia provided the same one is used throughout, and says Fridericia may be preferable. ESC and ESMO say to correct electrolytes. ESC says to avoid other QT-prolonging medicines if possible; ESMO says to use caution in people taking them. ESC interrupts treatment at 500 ms or more and IC-OS recommends considering a change of treatment only above 500 ms; ESMO gives no QTc threshold. Where the guidelines differ from the labels, both are shown. Starting: the ESC algorithm sends people with a baseline QTcF above 480 ms for cardio-oncology evaluation, while the ribociclib label allows a start only below 450 ms and the quizartinib and revumenib labels do not allow one above 450 ms. Above 480 ms and below 500 ms: ESC continues treatment with weekly ECGs; the ribociclib and revumenib labels interrupt above 480 ms, and the quizartinib label reduces the dose without interruption. A rise of more than 60 ms: ESC and IC-OS say it should not routinely change treatment below 500 ms; the trial grading scale (CTCAE, as IC-OS reports it) counts a 60 ms change from baseline as grade 3; the adagrasib label withholds for a rise of more than 60 ms and the revumenib label interrupts for one; and the ribociclib label stops treatment for either a QTcF above 500 ms or a rise of more than 60 ms when it comes with torsades de pointes, polymorphic ventricular tachycardia, syncope or signs of serious arrhythmia. Risk class: ESC Table 9 (2022) places quizartinib and midostaurin in its low-risk group, while the quizartinib label (2026) carries a boxed warning for QT prolongation, torsades de pointes and cardiac arrest. For the dose of the cancer medicine, the ESC algorithm itself defers to the drug-specific protocol.
European Society of Cardiology (European Heart Journal); read from the publisher's PDF in an open university repository and from the Internet Archive capture of the publisher's page 2022 · IC-OS (European Heart Journal); read from the author accepted manuscript in the University of Glasgow repository (eprints.gla.ac.uk/251609), because the published text could not be read 2022 · ESMO (Annals of Oncology; Curigliano et al.) 2020 · Novartis, on DailyMed (US National Library of Medicine) 2026 · Daiichi Sankyo, on DailyMed (US National Library of Medicine) 2026 · AstraZeneca, on DailyMed (US National Library of Medicine) 2026 · Mirati Therapeutics, on DailyMed (US National Library of Medicine) 2026 · Syndax Pharmaceuticals, on DailyMed (US National Library of Medicine) 2026
Where it differs: ECG at baseline, once steady-state drug levels are reached, after each dose modification or any treatment interruption of more than 2 weeks; monthly for the first 3 months, then periodically according to the person's risk factors and the treatment.
Evidence: Figure 32 and its legend, and Recommendation Table 32: an ECG after any dose increase is Class I, Level C. Drug-specific ESC recommendations sit beside it: for ribociclib, QTc monitoring at baseline and at 14 and 28 days (Class I, Level A) and with any dose increase (Class I, Level B); for VEGF inhibitors in people at moderate or high risk of QTc prolongation, monthly for the first 3 months and every 3 to 6 months after that (Class I, Level C).
Where it differs: Ribociclib: before starting and at about day 14 of the first cycle, then as clinically indicated, with electrolytes before starting and at the start of each of the first 6 cycles. Quizartinib: before starting, weekly during induction and consolidation, weekly for at least the first month of maintenance and after dose escalation. Revumenib: before starting, at least weekly for the first 4 weeks, then at least monthly, and more often if needed in people at risk. Osimertinib: periodic ECGs and electrolytes in people with congenital long QT syndrome, heart failure, electrolyte abnormalities or QT-prolonging medicines. Adagrasib: before starting and as indicated in people with heart failure, slow heart rhythms, electrolyte abnormalities or unavoidable QT-prolonging medicines.
Evidence: Regulatory labels, not graded. ESC (2022) recommends QTc monitoring on ribociclib at baseline and at 14 and 28 days (Class I, Level A), and its narrative describes ECGs at day 14 of the first cycle, before the second cycle and with any dose increase; the label read here (2026) asks for baseline and about day 14, then as clinically indicated.
Novartis, on DailyMed (US National Library of Medicine) 2026 · Daiichi Sankyo, on DailyMed (US National Library of Medicine) 2026 · Syndax Pharmaceuticals, on DailyMed (US National Library of Medicine) 2026 · AstraZeneca, on DailyMed (US National Library of Medicine) 2026 · Mirati Therapeutics, on DailyMed (US National Library of Medicine) 2026 · European Society of Cardiology (European Heart Journal); read from the publisher's PDF in an open university repository and from the Internet Archive capture of the publisher's page 2022
Where it differs: Ribociclib: above 480 ms interrupt until 480 ms or less (early breast cancer resumes at the same dose, advanced disease at the next lower dose); above 500 ms interrupt and resume at the next lower dose, and stop if it recurs. Quizartinib: 481 to 500 ms reduce the dose without interruption; above 500 ms interrupt and resume at a reduced dose once below 450 ms; stop if it recurs despite dose reduction and correction of other factors. Osimertinib: above 500 ms on at least 2 separate ECGs, withhold until below 481 ms (or baseline) and resume at 40 mg. Revumenib: above 480 ms interrupt and correct low potassium and magnesium, restarting at the same dose (above 480 to 500 ms) or a reduced dose (above 500 ms, or a rise of more than 60 ms from baseline) once at or below 480 ms. Adagrasib: above 500 ms or a rise of more than 60 ms from baseline, withhold until below 481 ms or back to baseline, then resume at the next lower dose. All stop permanently for torsades de pointes or signs of serious or life-threatening arrhythmia.
Evidence: Regulatory labels, not graded. ESC sets one rule for any QT-prolonging cancer medicine: interrupt at 500 ms or more; once QTcF is 480 ms or less, resume at the same or a reduced dose by the drug's own protocol; if it settles only to between 480 and 500 ms, consider restarting at a reduced dose (Class IIb); if it stays at 500 ms or more, a multidisciplinary team discusses other cancer treatments (Class I).
Novartis, on DailyMed (US National Library of Medicine) 2026 · Daiichi Sankyo, on DailyMed (US National Library of Medicine) 2026 · AstraZeneca, on DailyMed (US National Library of Medicine) 2026 · Syndax Pharmaceuticals, on DailyMed (US National Library of Medicine) 2026 · Mirati Therapeutics, on DailyMed (US National Library of Medicine) 2026 · European Society of Cardiology (European Heart Journal); read from the publisher's PDF in an open university repository and from the Internet Archive capture of the publisher's page 2022
Where it differs: The label contraindicates quizartinib in severe hypokalaemia, severe hypomagnesaemia, long QT syndrome, or a history of ventricular arrhythmias or torsades de pointes, and it is supplied only through a Risk Evaluation and Mitigation Strategy programme.
Evidence: Boxed warning in the US label. The label says: "VANFLYTA is available only through a restricted program called the VANFLYTA Risk Evaluation and Mitigation Strategy (REMS)." Arrangements in other countries were not read.
Daiichi Sankyo, on DailyMed (US National Library of Medicine) 2026
Where it differs: The ribociclib label says to avoid tamoxifen with it because the combination lengthened the QT interval more; ESC says the prescribing information does not recommend the combination.
Evidence: In MONALEESA-7, a QTcF rise of more than 60 ms occurred in 14 of 87 patients (16 per cent) on ribociclib with tamoxifen and 18 of 245 (7 per cent) on ribociclib with a non-steroidal aromatase inhibitor (label).
Novartis, on DailyMed (US National Library of Medicine) 2026 · European Society of Cardiology (European Heart Journal); read from the publisher's PDF in an open university repository and from the Internet Archive capture of the publisher's page 2022
| Recommendation | Grade, as printed | Source |
|---|---|---|
| Baseline ECG with QTc before potentially cardiotoxic treatment | [I, A] | ESMO (Annals of Oncology; Curigliano et al.) 2020 |
| Discontinue the QT-prolonging cancer therapy in patients who develop torsades de pointes or sustained ventricular tachyarrhythmias | Class I, Level C | European Society of Cardiology (European Heart Journal); read from the publisher's PDF in an open university repository and from the Internet Archive capture of the publisher's page 2022 |
| Temporarily interrupt at an asymptomatic QTcF of 500 ms or more, with an ECG every 24 hours until it resolves | Class I, Level C | European Society of Cardiology (European Heart Journal); read from the publisher's PDF in an open university repository and from the Internet Archive capture of the publisher's page 2022 |
| Withdraw any offending drug and correct electrolytes and other risk factors at a QTcF of 500 ms or more | Class I, Level C | European Society of Cardiology (European Heart Journal); read from the publisher's PDF in an open university repository and from the Internet Archive capture of the publisher's page 2022 |
| Weekly ECG in asymptomatic patients with QTcF 480 to 500 ms on a QT-prolonging cancer therapy | Class I, Level C | European Society of Cardiology (European Heart Journal); read from the publisher's PDF in an open university repository and from the Internet Archive capture of the publisher's page 2022 |
| 12-lead ECG after any dose increase of a QT-prolonging cancer therapy | Class I, Level C | European Society of Cardiology (European Heart Journal); read from the publisher's PDF in an open university repository and from the Internet Archive capture of the publisher's page 2022 |
| Multidisciplinary discussion before restarting after significant QTcF prolongation | Class I, Level C | European Society of Cardiology (European Heart Journal); read from the publisher's PDF in an open university repository and from the Internet Archive capture of the publisher's page 2022 |
| Restarting the culprit medicine may be considered, ideally at a reduced dose | Class IIb, Level C | European Society of Cardiology (European Heart Journal); read from the publisher's PDF in an open university repository and from the Internet Archive capture of the publisher's page 2022 |
| Weekly ECG for the first 4 to 6 weeks and then monthly after restarting | Class I, Level C | European Society of Cardiology (European Heart Journal); read from the publisher's PDF in an open university repository and from the Internet Archive capture of the publisher's page 2022 |
| A QTc of 500 ms or more carries a two to three times higher risk of torsades de pointes “a QTc ≥ 500 ms is associated with a two- to three-fold higher risk for TdP, while TdP rarely occurs when QTc is <500 ms” | Guideline text; not graded | European Society of Cardiology (European Heart Journal); read from the publisher's PDF in an open university repository and from the Internet Archive capture of the publisher's page 2022 |
| QTc monitoring at baseline and at 14 and 28 days in all patients receiving ribociclib | Class I, Level A | European Society of Cardiology (European Heart Journal); read from the publisher's PDF in an open university repository and from the Internet Archive capture of the publisher's page 2022 |
| QTc monitoring with any dose increase of ribociclib | Class I, Level B | European Society of Cardiology (European Heart Journal); read from the publisher's PDF in an open university repository and from the Internet Archive capture of the publisher's page 2022 |
| A change of more than 60 ms from baseline is clinically insignificant if the QT stays below 500 ms; consider changing cancer treatment only above 500 ms | Consensus statement text; not graded | IC-OS (European Heart Journal); read from the author accepted manuscript in the University of Glasgow repository (eprints.gla.ac.uk/251609), because the published text could not be read 2022 |
| Either Bazett or Fridericia, used consistently; Fridericia may be preferable in cancer “Fridericia’s formula may be preferable in the cancer population as there is less over- and under-correction in patients with tachycardia or bradycardia, respectively.” | Consensus text; not graded | ESMO (Annals of Oncology; Curigliano et al.) 2020 |
| Ribociclib: stop for a QTcF above 500 ms or a rise of more than 60 ms when accompanied by a serious arrhythmia or syncope “Permanently discontinue KISQALI if QTcF interval prolongation is either > 500 ms or > 60 ms change from baseline AND associated with any of the following: Torsades de Pointes, polymorphic ventricular tachycardia, syncope, or signs/symptoms of serious arrhythmia.” | Regulatory label; not graded | Novartis, on DailyMed (US National Library of Medicine) 2026 |
| Quizartinib: do not start or escalate the dose at a QTcF above 450 ms (boxed warning) “Do not initiate treatment with VANFLYTA or escalate the VANFLYTA dose if the QT interval corrected by Fridericia's formula (QTcF) is greater than 450 ms” | Regulatory label; not graded | Daiichi Sankyo, on DailyMed (US National Library of Medicine) 2026 |
| Revumenib: ECG before starting, weekly for 4 weeks, then monthly “Perform an electrocardiogram (ECG) prior to the initiation of REVUFORJ, at least once a week for the first 4 weeks, and at least monthly thereafter.” | Regulatory label; not graded | Syndax Pharmaceuticals, on DailyMed (US National Library of Medicine) 2026 |
| Adagrasib: ECG and electrolytes in people at risk; correct electrolytes “Monitor ECGs and electrolytes, particularly potassium and magnesium, prior to starting KRAZATI, during concomitant use, and as clinically indicated in patients with congestive heart failure, bradyarrhythmias, electrolyte abnormalities, and in patients who are unable to avoid concomitant medications that are known to prolong the QT interval.” | Regulatory label; not graded | Mirati Therapeutics, on DailyMed (US National Library of Medicine) 2026 |
Shares 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS), Drug, herbal and food interaction review for anticancer treatment, Heart risk assessment and monitoring before, during and after heart-toxic cancer treatment, Cardiotoxicity (LVEF decline, cardiomyopathy) and the tags protocol, cardio-oncology, side-effect-management.
Shares 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS), Heart risk assessment and monitoring before, during and after heart-toxic cancer treatment, Cardiotoxicity (LVEF decline, cardiomyopathy), Cardio-oncology and the tags protocol, cardio-oncology.
Shares 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS), European Society for Medical Oncology (ESMO) and the tags protocol, cardio-oncology.
Shares Pazopanib, Adagrasib, European Society for Medical Oncology (ESMO) and the tag protocol.
Shares QT prolongation, European Society for Medical Oncology (ESMO) and the tag protocol.
Shares European Society for Medical Oncology (ESMO) and the tag protocol.
Shares European Society for Medical Oncology (ESMO) and the tag protocol.
Shares European Society for Medical Oncology (ESMO) and the tag protocol.